Name | Number of supported studies | Average coverage | |
---|---|---|---|
glutamatergic neuron | 7 studies | 40% ± 27% | |
endothelial cell | 6 studies | 25% ± 7% | |
astrocyte | 6 studies | 29% ± 10% | |
oligodendrocyte | 6 studies | 27% ± 7% | |
interneuron | 5 studies | 37% ± 22% | |
GABAergic neuron | 5 studies | 42% ± 20% | |
neuron | 4 studies | 23% ± 9% | |
oligodendrocyte precursor cell | 4 studies | 34% ± 9% | |
brush cell | 4 studies | 32% ± 15% | |
T cell | 3 studies | 28% ± 11% | |
squamous epithelial cell | 3 studies | 35% ± 21% | |
CD16-positive, CD56-dim natural killer cell, human | 3 studies | 17% ± 1% | |
CD4-positive, alpha-beta T cell | 3 studies | 21% ± 4% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 22% ± 6% | |
epithelial cell | 3 studies | 37% ± 6% | |
CD8-positive, alpha-beta T cell | 3 studies | 17% ± 2% | |
CD8-positive, alpha-beta memory T cell | 3 studies | 20% ± 2% | |
gamma-delta T cell | 3 studies | 24% ± 7% | |
innate lymphoid cell | 3 studies | 22% ± 2% | |
group 3 innate lymphoid cell | 3 studies | 34% ± 6% | |
endothelial cell of lymphatic vessel | 3 studies | 22% ± 4% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 8 studies | 34% ± 19% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 2300.90 | 245 / 245 | 100% | 15.70 | 502 / 502 |
brain | 100% | 2062.71 | 2638 / 2642 | 99% | 16.75 | 701 / 705 |
thymus | 100% | 3183.02 | 653 / 653 | 99% | 20.31 | 600 / 605 |
breast | 100% | 2093.03 | 459 / 459 | 97% | 12.78 | 1088 / 1118 |
lung | 99% | 1773.61 | 575 / 578 | 98% | 10.85 | 1128 / 1155 |
adrenal gland | 100% | 1697.28 | 257 / 258 | 97% | 11.90 | 224 / 230 |
esophagus | 100% | 3229.02 | 1443 / 1445 | 97% | 14.19 | 177 / 183 |
uterus | 100% | 3316.19 | 170 / 170 | 96% | 10.92 | 442 / 459 |
pancreas | 100% | 1650.15 | 328 / 328 | 94% | 8.26 | 167 / 178 |
bladder | 100% | 2779.90 | 21 / 21 | 92% | 7.77 | 462 / 504 |
ovary | 100% | 5869.90 | 180 / 180 | 92% | 7.19 | 394 / 430 |
stomach | 100% | 1915.58 | 359 / 359 | 91% | 8.87 | 260 / 286 |
intestine | 100% | 3778.65 | 966 / 966 | 91% | 7.33 | 479 / 527 |
kidney | 100% | 1429.03 | 89 / 89 | 89% | 8.18 | 806 / 901 |
skin | 100% | 2606.80 | 1807 / 1809 | 82% | 8.29 | 388 / 472 |
liver | 96% | 984.48 | 218 / 226 | 84% | 5.86 | 341 / 406 |
blood vessel | 100% | 2844.89 | 1335 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 2328.26 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 1599.57 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 13.47 | 45 / 45 |
adipose | 100% | 1971.37 | 1203 / 1204 | 0% | 0 | 0 / 0 |
heart | 94% | 1304.80 | 810 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 70% | 5.33 | 56 / 80 |
lymph node | 0% | 0 | 0 / 0 | 66% | 4.33 | 19 / 29 |
peripheral blood | 50% | 608.46 | 463 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006281 | Biological process | DNA repair |
GO_0070358 | Biological process | actin polymerization-dependent cell motility |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0070060 | Biological process | 'de novo' actin filament nucleation |
GO_0009267 | Biological process | cellular response to starvation |
GO_0034314 | Biological process | Arp2/3 complex-mediated actin nucleation |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0072332 | Biological process | intrinsic apoptotic signaling pathway by p53 class mediator |
GO_0043065 | Biological process | positive regulation of apoptotic process |
GO_0005856 | Cellular component | cytoskeleton |
GO_0031410 | Cellular component | cytoplasmic vesicle |
GO_0012505 | Cellular component | endomembrane system |
GO_0000421 | Cellular component | autophagosome membrane |
GO_0005654 | Cellular component | nucleoplasm |
GO_0031252 | Cellular component | cell leading edge |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0071933 | Molecular function | Arp2/3 complex binding |
GO_0008017 | Molecular function | microtubule binding |
GO_0003713 | Molecular function | transcription coactivator activity |
GO_0005515 | Molecular function | protein binding |
GO_0003779 | Molecular function | actin binding |
Gene name | JMY |
Protein name | Junction-mediating and -regulatory protein |
Synonyms | |
Description | FUNCTION: Acts both as a nuclear p53/TP53-cofactor and a cytoplasmic regulator of actin dynamics depending on conditions . In nucleus, acts as a cofactor that increases p53/TP53 response via its interaction with p300/EP300. Increases p53/TP53-dependent transcription and apoptosis, suggesting an important role in p53/TP53 stress response such as DNA damage. In cytoplasm, acts as a nucleation-promoting factor for both branched and unbranched actin filaments . Activates the Arp2/3 complex to induce branched actin filament networks. Also catalyzes actin polymerization in the absence of Arp2/3, creating unbranched filaments . Contributes to cell motility by controlling actin dynamics. May promote the rapid formation of a branched actin network by first nucleating new mother filaments and then activating Arp2/3 to branch off these filaments. Upon nutrient stress, directly recruited by MAP1LC3B to the phagophore membrane surfaces to promote actin assembly during autophagy . The p53/TP53-cofactor and actin activator activities are regulated via its subcellular location (By similarity). . |
Accessions | Q8N9B5 ENST00000396137.5 [Q8N9B5-1] |